Next generation theranostic pair offers new strategy to detect and treat metastatic kidney cancer

A newly developed radiotheranostic pair, 68Ga/177Lu-NYM096, can identify tumors and effectively deliver targeted radiotherapy to patients with metastatic clear cell renal cell carcinoma (ccRCC). Using a small-molecule compound, the new approach helps mitigate toxicity issues common with treatment, offering a safe and feasible strategy for those with end-stage disease. This research was published in the September issue of The Journal of Nuclear Medicine.

Read it at Medical Xpress ↗

← Front page